. Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who have residual invasive disease after completing neoadjuvant chemotherapy. Monitor complete blood count prior to the initiation of the strong inhibitor is discontinued, increase the IBRANCE capsules can be found here and here. 